牛牛AI助手已提取核心信息
Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 3,309 shares of common stock on February 23, 2024. The transaction was carried out at a price of $431.79 per share, resulting in a total value of approximately $1.43 million. Following the sale, Bozic's direct holdings in the company amount to 36,939 shares. The sale was executed to cover the payment of exercise price or tax liability by delivering or withholding securities, as indicated by the transaction code 'F'.
Carmen Bozic, EVP and CMO of Vertex Pharmaceuticals Inc. (VRTX), completed a sale of 3,309 shares of common stock on February 23, 2024. The transaction was carried out at a price of $431.79 per share, resulting in a total value of approximately $1.43 million. Following the sale, Bozic's direct holdings in the company amount to 36,939 shares. The sale was executed to cover the payment of exercise price or tax liability by delivering or withholding securities, as indicated by the transaction code 'F'.
Vertex Pharmicals Inc.（VRTX）执行副总裁兼首席营销官卡门·博齐奇于2024年2月23日完成了3,309股普通股的出售。该交易以每股431.79美元的价格进行，总价值约为143万美元。出售后，Bozic在该公司的直接持股量为36,939股。执行此次出售是为了通过交付或预扣证券来支付行使价或应纳税额，如交易代码 “F” 所示。
Vertex Pharmicals Inc.（VRTX）执行副总裁兼首席营销官卡门·博齐奇于2024年2月23日完成了3,309股普通股的出售。该交易以每股431.79美元的价格进行，总价值约为143万美元。出售后，Bozic在该公司的直接持股量为36,939股。执行此次出售是为了通过交付或预扣证券来支付行使价或应纳税额，如交易代码 “F” 所示。
有用
没用
该公告为独立文件：